title: Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy.
abstract: OBJECTIVE
  To evaluate the effectiveness of adjuvant chemotherapy in patients with pathological Stage T3 bladder cancer who had undergone radical cystectomy, and to determine the prognostic survival factors for adjuvant chemotherapy treatment.
  
  
  METHODS
  From January 1990 to October 2013, 202 patients underwent radical cystectomy and pelvic lymphadenectomy. Among them, 65 patients with non-organ-confined disease (pT3, N0-3, M0) diagnosed were investigated in this study. Thirty-one patients (48%) were treated with adjuvant chemotherapy and the remaining 34 patients (52%) were not.
  
  
  RESULTS
  Median age of all patients was 66 years, and median follow-up was 26.1 months. For all pT3 patients, overall survival and disease-free survival times were similar in the adjuvant chemotherapy and non-adjuvant chemotherapy groups. However, in the pT3b subgroup, median overall survival (47.0 vs. 10.6 months) and median disease-free survival (35.5 vs. 5.3 months) times were significantly prolonged for those who underwent adjuvant chemotherapy (P = 0.009 and 0.025). In patients with pathological lymph node metastatic (pN+), median overall survival (30.1 vs. 6.4 months) and median disease-free survival (15.7 vs. 3.5 months) times were significantly prolonged in the adjuvant chemotherapy group (P = 0.016 and 0.027). In addition, according to multivariate analysis in pT3b and/or pN+ subgroup patients, adjuvant chemotherapy status was an independent predictive factor for overall survival and disease-free survival.
  
  
  CONCLUSIONS
  Adjuvant chemotherapy did not significantly improve overall survival and disease-free survival when compared with all patients with pT3 who had received radical cystectomy in the non-adjuvant chemotherapy group. However, in the pT3b and pN+ subgroup, adjuvant chemotherapy demonstrated statistically significant benefits regarding overall survival and disease-free survival. Although these results could not support adjuvant chemotherapy use for all pT3 patients, the pT3b substage and/or pN+ may help identify patients with pT3 who could benefit from adjuvant chemotherapy.
authors.affiliation: Department of Urology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
authors.forename: Mariko
authors.initials: M
authors.lastname: Tabata
authors.affiliation: Department of Urology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan ikeda.masaomi@grape.plala.or.jp.
authors.forename: Masaomi
authors.initials: M
authors.lastname: Ikeda
authors.affiliation: Department of Urology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Urakami
authors.affiliation: Department of Urology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
authors.forename: Shintaro
authors.initials: S
authors.lastname: Takahashi
authors.affiliation: Department of Urology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
authors.forename: Kazushige
authors.initials: K
authors.lastname: Sakaguchi
authors.affiliation: Department of Urology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kurosawa
authors.affiliation: Department of Urology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Okaneya
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D015653:Cystectomy; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016019:Survival Analysis; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: adjuvant chemotherapy; pT3 bladder cancer; urothelial carcinoma